{
  "docId": "019de075-d8f1-727b-b893-5e9d6af9a579",
  "docSlug": "880c8a38f766d3eb6660c74e922f5744",
  "documentTitle": "MindMed | Investor Presentation Deck | 32 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 32,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "The slide uses a bulleted list format to highlight core business strengths and specific drug development programs (MM-120 and MM-402).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-d8f1-727b-b893-5e9d6af9a579/31",
  "deckHref": "/decks/019de075-d8f1-727b-b893-5e9d6af9a579",
  "deckJsonHref": "/decks/019de075-d8f1-727b-b893-5e9d6af9a579.json",
  "deckAnchorHref": "/decks/019de075-d8f1-727b-b893-5e9d6af9a579#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.78,
        "x": 0.057,
        "y": 0.87
      },
      "kind": "disclaimer",
      "text": "1. The company's ending Q2 2023 cash and cash equivalents of $116.9 million and committed credit facility are expected to fund operations into 2026, if certain milestones are achieved that unlock additional capital.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ea05932-b284-4f98-a2dc-9e54672f6683",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.88,
        "x": 0.057,
        "y": 0.17
      },
      "kind": "list",
      "text": "A leader in developing psychedelic product candidates to treat brain health disorders; Diversified pipeline of clinical programs targeting significant unmet medical needs; IP and R&D strategies intended to maximize market exclusivity and protection; Leveraging decades of research on clinical and preclinical potential of product candidates; Expertise in drug and digital medicine development and commercialization; Expected cash runway through key clinical readouts and into 2026; MM-120 (LSD D-tartrate) for the treatment of GAD and ADHD; MM-402 or R(-)-MDMA for the treatment of core symptoms of ASD",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7bc0e0de-2bd7-4b05-87f2-9ddf277a276b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.29,
        "x": 0.057,
        "y": 0.05
      },
      "kind": "title",
      "text": "Business Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68fcf2ff-bb4c-457c-b27b-67933694293e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "38aef948-c46c-49c6-86a0-e12fafebfa43",
      "evidence": "The slide provides a concise overview of the company's business highlights, summarizing key points.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}